This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): GFT-505, GFT505
Description: GFT505 is a multimodal and pluripotent medication for treatment of atherogenic dyslipidemia for an overweight patient with or without diabetes.
GFT505 is the result of a rational design process to identify a new SPPARM (Selective PPAR Modulator) based on the compatibility analysis of the structural/activity relationships for the different sub-types of PPAR receptors. GFT505 was discovered using the technical platform developed by Genfit to optimize the safety/efficacy ratio of the PPAR agonists. GFT505 is an oral treatment that acts primarily through 2 sub-types of PPAR (PPARa, PPARd) with a preferential action on PPARa.
Additional information available to subscribers only: